LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
Bryan E. Jones(Richard L. Roudebush VA Medical Center), Jason S. McLellan(The University of Texas at Austin), Lucas Kraft(AbCellera (Canada)), David R. Martinez(University of North Carolina at Chapel Hill), Deepa Balasubramaniam(Eli Lilly (United States)), Davide Pellacani(AbCellera (Canada)), Ralph S. Baric(University of North Carolina at Chapel Hill), Patricia Brown‐Augsburger(Eli Lilly (United States)), Rodrigo Goya(Canada's Michael Smith Genome Sciences Centre), Adil Mohamed(University of Alberta), Kizzmekia S. Corbett(Harvard University), Solmaz Sobhanifar(AbCellera (Canada)), Hayley M. Belli(New York University), Marie I. Samanovic(NYU Langone Health), Roza Bidshahri(AbCellera (Canada)), J. Hendle(Eli Lilly (United States)), Meike Dittmann(New York University), Robert W. Cross(The University of Texas Medical Branch at Galveston), Kevin R. Jepson(AbCellera (Canada)), Maia A. Smith(AbCellera (Canada)), Jory A. Goldsmith(The University of Texas at Austin), Christopher M. Wiethoff(Eli Lilly (United States)), Daniel Wrapp(Duke University), Maren de Vries(New York University), Lingshu Wang(National Institutes of Health), Krithika Muthuraman(AbCellera (Canada)), Stefanie Žentelis(AbCellera (Canada)), Richard E. Higgs(Eli Lilly (United States)), Viktoriya Borisevich(Galveston College), Anna Pustilnik(Eli Lilly (United States)), Thomas W. Geisbert(The University of Texas Medical Branch at Galveston), Nicole V. Johnson(The University of Texas at Austin), Mark J. Mulligan(New York University), Olubukola M. Abiona(National Institutes of Health), Samuel J. Hinshaw(AbCellera (Canada)), Shawn Berens(Washington State University), Denisa Foster(Eli Lilly (United States)), Yuri Hwang(AbCellera (Canada)), Kathryn Westendorf(AbCellera (Canada)), Thomas P. Cujec(Eli Lilly (United States)), Marissa H. Piper(Eli Lilly (United States)), Franz J. Triana(Eli Lilly (United States)), Julian Davies(Eli Lilly (United States)), Ping Xiang(China International Science and Technology Cooperation), David W. Collins, Ching‐Lin Hsieh(The University of Texas at Austin), Andrew C. Adams(Beth Israel Deaconess Medical Center), Jamie L. Blackbourne(Eli Lilly (United States)), Beverly A. Heinz(Eli Lilly (United States)), Sean A. Tycho(AbCellera (Canada))
Cited by 175
Related Papers
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
|Science|2020|9.8k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k
Site-specific glycan analysis of the SARS-CoV-2 spike
|Science|2020|1.7k